{"id":69381,"date":"2013-01-05T01:44:23","date_gmt":"2013-01-05T01:44:23","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/gene-therapy-local-group-seeks-answers-to-cancer.php"},"modified":"2013-01-05T01:44:23","modified_gmt":"2013-01-05T01:44:23","slug":"gene-therapy-local-group-seeks-answers-to-cancer","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/gene-therapy\/gene-therapy-local-group-seeks-answers-to-cancer.php","title":{"rendered":"Gene therapy: Local group seeks \u2018answers to cancer\u2019"},"content":{"rendered":"<p><p>    Written by Kait Shea, Assistant    Editor    Friday, 04 January 2013 11:00  <\/p>\n<p>    There may not be a cure for cancer just yet, but the Alliance    for Cancer Gene Therapy (ACGT), a nonprofit established by a    Greenwich couple thats dedicated to gene therapy, is making    big strides in treatment.  <\/p>\n<p>    The Stamford-based organization is the only nonprofit in the    United States dedicated exclusively to cell and gene cancer    therapy research. One hundred percent of all contributions to    ACGT go directly to research and fund grants with leading    scientists in the country, representing 28 prestigious medical    institutions. Many feel that because of this ACGT has played a    major role in what many doctors believe may be the key to    healing those plagued by the disease.  <\/p>\n<p>    In an interview with the Post, Ms. Netter said she and her late    husband realized this really is a key to perhaps finding the    answers to cancer and immediately sought to put their    energies and resources into it on hope and faith. After a    year of fund raising, the couple officially embarked on their    mission to provide grants to the nations leading scientific    investigators for cancer gene therapy research.  <\/p>\n<p>    With the help of ACGTs Scientific Advisory Council, a group    composed of leading scientists and doctors who conduct rigorous    reviews of grants to ensure that the most promising cancer gene    therapy projects are given funding, the Netters awarded more    than $22 million in grants within the first 10 years of    launching their organization.  <\/p>\n<p>    The latest strides in gene therapy projects funded by ACGT,    however, are the most exciting the organization has seen, Ms.    Netter said. The alliance played a significant part in the    recent leukemia study pioneered by scientists at the Perelman    School of Medicine at the University of Pennsylvania. ACGT    provided the initial funds for the study, which has found    success using immune-mediated gene therapy for leukemia and    lymphoma.  <\/p>\n<p>    According to Ms. Netter, the therapy used involves removing    immune cells from the body of the patient, bioengineering and    strengthening them, then reinfusing them into the patient using    a gutted out HIV vector, which reprograms the patients immune    system genetically to kill cancer. The T cells directly target    and kill cancer cells and circulate through the body for at    least a few years, and Ms. Netter called it an enormous    breakthrough.  <\/p>\n<p>    Initial ACGT grants for the immune mediated gene therapy    project were awarded in 2004 to Carl June of the Abramson    Family Cancer Research Institute at the University of    Pennsylvania and to Michel Sadelain, of Memorial    Sloan-Kettering Cancer Center, Gene Therapy and Gene Expression    Laboratory, in New York City. Preliminary results were issued    by Dr. June in August 2011, with additional results released in    December 2012, delivering some of the most promising results    seen to date in the search for a cure.  <\/p>\n<p>    The clinical trial participants, all of whom had advanced    cancers, included 10 adult patients with chronic lymphocytic    leukemia who were treated at the Hospital of the University of    Pennsylvania and two children with acute lymphoblastic leukemia    who were treated at the Childrens Hospital of Philadelphia.    Two of the first three adult patients treated with the protocol    remained healthy and in full remission more than two years    after their treatment, with the engineered cells still    circulating in their bodies. Currently, nine out of the 12    participants show their disease in remission.  <\/p>\n<p>    Perhaps the most amazing story of recovery, Ms. Netter said,    was that of now 7-year-old Emma Whitehead, who was on the brink    of death, suffering from acute lymphoblastic leukemia. After    trying traditional cancer treatments like chemotherapy without    any improvement, Emmas parents decided to try the    experimental T-cell therapy. And although the treatment    nearly killed Emma, her health rapidly improved and she emerged    cancer-free, Ms. Netter said. The young girl is now out of the    hospital and leading the life of a regular second grader, with    eight months of remission from the disease under her belt.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Read the rest here:<\/p>\n<p><a target=\"_blank\" href=\"http:\/\/www.greenwich-post.com\/online\/daily-featured\/local-news\/101822-gene-therapy-local-group-seeks-answers-to-cancer-.html\" title=\"Gene therapy: Local group seeks \u2018answers to cancer\u2019\">Gene therapy: Local group seeks \u2018answers to cancer\u2019<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Written by Kait Shea, Assistant Editor Friday, 04 January 2013 11:00 There may not be a cure for cancer just yet, but the Alliance for Cancer Gene Therapy (ACGT), a nonprofit established by a Greenwich couple thats dedicated to gene therapy, is making big strides in treatment. The Stamford-based organization is the only nonprofit in the United States dedicated exclusively to cell and gene cancer therapy research.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/gene-therapy\/gene-therapy-local-group-seeks-answers-to-cancer.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[24],"tags":[],"class_list":["post-69381","post","type-post","status-publish","format-standard","hentry","category-gene-therapy"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/69381"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=69381"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/69381\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=69381"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=69381"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=69381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}